Abstract: The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load. The medicament preferably contains no silidianin and/or no silichristin and/or no isosilibinin.

Abstract: The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load. The medicament preferably contains no silidianin and/or no silichristin and/or no isosilibinin.

Abstract: The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load.

Abstract: The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (plantaginis ovatae semen). The composition can advantageously be manufactured by fluidized bed granulation. The composition is in particular free of guar gum, is dust-free, is dispersible in water and has a pleasant taste and can be supplemented straightforwardly with vitamins, minerals, trace elements and the like.

Abstract: The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (plantaginis ovatae semen). The composition can advantageously be manufactured by fluidized bed granulation. The composition is in particular free of guar gum, is dust-free, is dispersible in water and has a pleasant taste and can be supplemented straightforwardly with vitamins, minerals, trace elements and the like.

Abstract: The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (plantaginis ovatae semen). The composition can advantageously be manufactured by fluidized bed granulation. The composition is in particular free of guar gum, is dust-free, is dispersible in water and has a pleasant taste and can be supplemented straightforwardly with vitamins, minerals, trace elements and the like.

Abstract: The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (plantaginis ovatae semen). The composition can advantageously be manufactured by fluidized bed granulation. The composition is in particular free of guar gum, is dust-free, is dispersible in water and has a pleasant taste and can be supplemented straightforwardly with vitamins, minerals, trace elements and the like.

Abstract: The present invention provides a process for the production of a flavanolignan preparation with an improved liberation in comparison with one of the pure flavanolignans, characterized in that a) an aqueous-alcoholic solution of pharmaceutically-acceptable carrier materials and wetting agents is prepared, a flavanolignan is suspended in this solution and the mixture obtained is heated to the boiling temperature in order to form a clear solution or b) a flavanolignan and a wetting agent is suspended in alcohol, the suspension obtained is heated with stirring up to the formation of a clear solution, this is mixed with an aqueous solution of pharmaceutically-acceptable carrier materials and the mixture obtained is heated with stirring until a clear solution is present and that subsequently the clear solution obtained according to a) or b) is concentrated for the formation of a co-precipitate, filtered and the resulting co-precipitate dried in a vacuum.

Abstract: The present invention provides compounds of the general formula: ##STR1## where R.sub.1 is a hydrogen atom or a methoxy or ethoxy radical and R.sub.2 and R.sub.3 are hydrogen atoms or R.sub.2 and R.sub.3 together represent an aromatic carbon-carbon bond and R.sub.1 is a hydrogen atom, a hydroxyl group or an ethoxy radical; and the pharmaceutically acceptable salts thereof.The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them, as well as their use in therapy.

Abstract: In a method of diagnosing obstructive sleep apnea, snoring and respiration sounds made by a patient, as well as the patient's heart rate, are recorded while the patient is sleeping. Signals indicative of snoring sounds and the time intervals therebetween are produced from the respiration sounds and recorded, and a first respiration disturbance index representing the number of intervals per hour between episodes of snoring is calculated. Signals indicative of the patient's heart rate are likewise produced and recorded, and the average heart rate is calculated. A second respiration disturbance index representing the number of episodes per hour in which the patient's heart rate remained at 90 to 109% of its average rate is calculated. A physician can then evaluate the first and second disturbance indices to determine whether obstructive apnea is indicated.Apparatus for practicing the method is also disclosed.

Abstract: An injection syringe for medical purposes, in which the syringe plunger or a plunger-side end of the syringe cylinder is shaped or provided with components to ensure at least one flow passage or connection between an inner cylindrical space of the cylinder and outer environment, when the plunger is partially, but not completely, introduced into the syringe cylinder.

Abstract: The present invention provides a process for the preparation of substantially pure silibinin from the fruit of Silybum marianum, as well as pharmaceutical compositions containing it for the treatment of diseases of the liver.

Abstract: New 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonine and -1,4-benzoxazonine compounds of the formula ##STR1## have useful pharmaceutical properites. They are prepared from ketones of the formula ##STR2## via a lactone intermediate. In the formula, the various R substitutes are generally hydrogen or alkyl, with R.sup.4 also being halogen or alkoxy and R.sup.3 R.sup.3' also being phenyl. R.sup.1 may be joined with R.sup.5 /R.sup.5' in a 5- to 7-membered ring possibly interrupted by O, S, SO.sub.2 or amino. One of X and Y is CH.sub.2 ; the other is amino. The starting ketones also have pharmaceutical properties. The lactone intermediates are new compounds.

Abstract: A method for preparing azoniaspironotropanol esters, esters thus produced, and methods of use for these is disclosed. The esters are effective as broncholytics and as agents in therapy of asthmatic conditions.

Abstract: The present invention is concerned with the use of azoniaspironortropanol esters of the general formula: ##STR1## wherein R signifies one of the following radicals: (a) an alkylene radical of the general formula: ##STR2## in which R.sub.3 is a hydrogen atom or an alkyl, benzyl, aryl or alkoxy radical and n is a whole number of from 1 to 4,(b) an alkenyl radical of the general formula: ##STR3## in which R.sub.4 and R.sub.5, which can be the same or different, are hydrogen atoms or alkyl or alkenyl radicals and n is a whole number of from 1 to 4,(c) an azaalkylene radical of the general formula: ##STR4## in which R.sub.6 is a hydrogen atom or an alkyl, alkoxycarbonyl or acyl radical and n is a whole number of from 2 to 4,(d) an oxaalkylene radical of the general formula:--(CH.sub.2).sub.n --O--(CH.sub.2).sub.